Pediatric and Adolescent Migraine — FDA Approvals, Off-Label Use, and PA Considerations
Three CGRP mAbs have FDA pediatric approval — step therapy is reduced but not eliminated, and teratogenicity bypass is stronger for adolescents than adults.
PA impact: This card directly affects prior authorization outcomes. Documentation language from this card can be used in PA letters and appeals.
What is FDA-approved and for what age. Three CGRP mAbs have FDA pediatric approval: galcanezumab (Emgality) for age 6 and older, erenumab (Aimovig) and fremanezumab (Ajovy) for age 12 and older. For acute treatment, rizatriptan is FDA-approved from age 6; sumatriptan nasal spray and several other triptans are approved from age 12. These approvals define the PA pathway — on-label requests follow standard step therapy, off-label requests require Medical Necessity documentation.
Step therapy is reduced but not eliminated. Most payers apply lighter step therapy for pediatric patients. For children age 6–11 requesting a CGRP mAb, document failure of one oral preventive class at a 4–8 week trial — not the two-class adult standard. For adolescents 12–17, some payers apply adult criteria while others accept one-class failure. The Vault identifies the specific payer's pediatric step therapy requirement. For all pediatric patients, if the request is denied, appeal citing the 2024 AHS Consensus Statement that explicitly supports earlier access to CGRP preventives in children and adolescents.
Teratogenicity bypass is stronger in adolescents. Valproate carries a triple FDA Black Box warning (neural tube defects, decreased IQ, autism spectrum risk) and should not be prescribed to females age 12–17 unless no alternatives exist and strict contraception is confirmed. Topiramate carries its own teratogenicity risk (cleft lip/palate, SGA neonates). For female adolescents, these contraindications bypass both drug classes from step therapy — document: "Topiramate and valproate contraindicated due to teratogenicity risk in a female of reproductive age. Proceeding directly to CGRP preventive."
Gepants in adolescents are off-label but clinically supported. Ubrogepant and rimegepant are FDA-approved for adults only, but the 2024 AHS Consensus Statement explicitly supports their use in adolescents when triptans are contraindicated or have failed. Expect an initial denial and prepare a Medical Necessity appeal citing the AHS position. The Vault generates the appropriate appeal language.
Ready to run a PA?
The PA Engine applies this guidance automatically — paste a clinical note and get a complete, payer-specific PA letter in under a minute. Free, no account required.
Run a PA — free →Citations: FDA approvals: galcanezumab (age 6+), erenumab/fremanezumab (age 12+), rizatriptan (age 6+) | AAN Pediatric Migraine Guidelines — Oskoui M et al., Neurology 2019;93(11):500-509. doi:10.1212/WNL.0000000000008367 | AHS 2024 Consensus on pediatric gepant use.